Silverback Raises $78.5m To Test Localized Therapy Delivered Systemically In Patients

With $78.5m in series B venture capital, Silverback Therapeutics Inc. will begin its first clinical trial later this year to determine whether its lead antibody-drug conjugate (ADC) SBT6050, which links a HER2-targeted antibody with a TLR8 agonist, will duplicate the company’s preclinical results that showed the ADC provided potent activation of myeloid cells and reprogrammed the tumor microenvironment.

Silverback has now raised more than $125m to date, including a series A extension that brought its initial funding round to $47.5m in September 2018 with the backing of founding investor OrbiMed Advisors plus Celgene Corp. (now Bristol-Myers Squibb) and Alexandria Venture Investments. (Also see "Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B" - Scrip, 26 September, 2018